William Blair Investment Management LLC Has $220 Million Stock Position in Globus Medical, Inc. $GMED

William Blair Investment Management LLC lowered its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 10.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 2,519,782 shares of the medical device company’s stock after selling 299,383 shares during the period. William Blair Investment Management LLC’s holdings in Globus Medical were worth $220,002,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Fideuram Intesa Sanpaolo Private Banking S.P.A. acquired a new stake in Globus Medical during the fourth quarter worth approximately $1,330,000. Legato Capital Management LLC grew its stake in Globus Medical by 2.6% in the fourth quarter. Legato Capital Management LLC now owns 23,228 shares of the medical device company’s stock valued at $2,028,000 after acquiring an additional 595 shares during the period. Meiji Yasuda Asset Management Co Ltd. acquired a new stake in Globus Medical in the fourth quarter valued at approximately $223,000. Global Retirement Partners LLC grew its stake in Globus Medical by 692.8% in the fourth quarter. Global Retirement Partners LLC now owns 5,058 shares of the medical device company’s stock valued at $442,000 after acquiring an additional 4,420 shares during the period. Finally, PNC Financial Services Group Inc. grew its stake in Globus Medical by 31.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,679 shares of the medical device company’s stock valued at $1,020,000 after acquiring an additional 2,771 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

Insider Buying and Selling at Globus Medical

In other news, EVP Kelly Huller sold 20,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 18.38% of the stock is owned by corporate insiders.

Globus Medical Stock Up 0.3%

GMED stock opened at $84.84 on Friday. Globus Medical, Inc. has a twelve month low of $51.79 and a twelve month high of $101.40. The stock’s 50 day moving average is $87.26 and its 200-day moving average is $87.80. The firm has a market capitalization of $11.52 billion, a PE ratio of 19.73, a P/E/G ratio of 1.75 and a beta of 1.00.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company had revenue of $759.85 million for the quarter, compared to analyst estimates of $740.35 million. During the same quarter last year, the company earned $0.68 earnings per share. The company’s revenue for the quarter was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts anticipate that Globus Medical, Inc. will post 4.74 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on GMED. Wall Street Zen cut Globus Medical from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 9th. Truist Financial set a $115.00 price objective on Globus Medical in a research note on Wednesday, February 25th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Barclays raised their price objective on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Finally, TD Cowen raised Globus Medical to a “strong-buy” rating in a research note on Tuesday, January 27th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Globus Medical has an average rating of “Moderate Buy” and an average price target of $106.36.

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.